Tempest Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Tempest Therapeutics, Inc. (TPST) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $29.00 thousand for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-13.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2021-05-13
- Tempest Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2021-03-31 was $29.00K.
- Tempest Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2020-12-31 was $0.00, a 100.00% decline year-over-year.
- Tempest Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- Tempest Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2020-06-30 was $1.00K, a 99.80% decline year-over-year.
- Tempest Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2020 was $1.00K, a 99.86% decline from fiscal 2019.
- Tempest Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2019 was $700.00K.
- Tempest Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2017 was $3.00M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2021-03-31 | $29.00K 10-Q · filed 2021-05-13 | $29.00K derived: sum of 2 quarters · filed 2021-05-13 | $29.00K derived: sum of 3 quarters · filed 2021-05-13 | $30.00K derived: sum of 4 quarters · filed 2021-05-13 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $0.00 derived: sum of 2 quarters · filed 2021-03-29 | $1.00K derived: sum of 3 quarters · filed 2021-03-29 | $1.00K 10-K · filed 2021-03-29 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $1.00K derived: sum of 2 quarters · filed 2020-11-09 | $1.00K 10-Q · filed 2020-11-09 | $201.00K derived: sum of 4 quarters · filed 2021-03-29 |
| 2020-06-30 | $1.00K 10-Q · filed 2020-08-10 | $1.00K 10-Q · filed 2020-08-10 | $201.00K derived: sum of 3 quarters · filed 2021-03-29 | $701.00K derived: sum of 4 quarters · filed 2021-03-29 |
| 2020-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2021-03-29 | $200.00K derived: sum of 2 quarters · filed 2021-03-29 | $700.00K derived: sum of 3 quarters · filed 2021-03-29 | $1.20M derived: sum of 4 quarters · filed 2021-03-29 |
| 2019-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $700.00K derived: sum of 2 quarters · filed 2021-03-29 | $1.20M derived: sum of 3 quarters · filed 2021-03-29 | $700.00K 10-K · filed 2021-03-29 |
| 2019-09-30 | $500.00K 10-Q · filed 2020-11-09 | $1.00M derived: sum of 2 quarters · filed 2020-11-09 | $500.00K 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $500.00K 10-Q · filed 2020-08-10 | $500.00K 10-Q · filed 2020-08-10 | ||
| 2017-12-31 | $3.00M 10-K · filed 2019-04-01 | |||
| 2014-06-30 | $600.00K 10-Q · filed 2014-08-07 | $1.60M 10-Q · filed 2014-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |